In these breast cancer patients treated with HBOT for LRITT, the patient-reported outcomes were positive and improvements were observed. HBOT was a well-tolerated treatment for LRITT and its side-effects were both minimal and reversible.
No takes yet. Share an insight, caveat, or question.
Teguh et al. (2016) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: